Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedSep 10, 2025
DataAggregated Company Financials
Companies293
  • 7D0.5%
  • 3M1.0%
  • 1Y-10.6%
  • YTD0.08%

In the last week, Pharma has been flat. Unfortunately though, the industry is down 11% over the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 10 Sep 2025US$1.8tUS$387.9bUS$61.0b19x29.4x4.6x
Fri, 08 Aug 2025US$1.7tUS$383.7bUS$57.1b18.3x30.3x4.5x
Sun, 06 Jul 2025US$1.7tUS$382.7bUS$61.3b18.3x28.5x4.6x
Tue, 03 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x27.6x4.4x
Thu, 01 May 2025US$1.8tUS$378.6bUS$63.0b17.2x28.9x4.8x
Sat, 29 Mar 2025US$1.8tUS$381.2bUS$41.2b15x44.6x4.8x
Mon, 24 Feb 2025US$1.9tUS$381.1bUS$39.0b18.6x48.6x5x
Wed, 22 Jan 2025US$1.8tUS$369.3bUS$31.2b19x56.1x4.7x
Fri, 20 Dec 2024US$1.8tUS$369.4bUS$31.1b16.9x57.1x4.8x
Sun, 17 Nov 2024US$1.8tUS$373.9bUS$30.5b19.1x58.5x4.8x
Tue, 15 Oct 2024US$2.0tUS$364.2bUS$25.3b18.7x80.1x5.6x
Thu, 12 Sep 2024US$2.0tUS$364.2bUS$25.5b18.5x79.5x5.6x
Sat, 10 Aug 2024US$1.9tUS$362.1bUS$22.0b17.1x87.8x5.3x
Mon, 08 Jul 2024US$2.0tUS$357.6bUS$13.8b15.1x141.8x5.5x
Wed, 05 Jun 2024US$1.9tUS$358.3bUS$14.1b15.3x135.5x5.3x
Fri, 03 May 2024US$1.9tUS$361.6bUS$16.3b22.2x113.9x5.1x
Sun, 31 Mar 2024US$1.9tUS$355.2bUS$22.6b22.7x84.4x5.4x
Tue, 27 Feb 2024US$1.9tUS$355.2bUS$23.9b24.2x80x5.4x
Thu, 25 Jan 2024US$1.8tUS$375.2bUS$33.9b25.9x51.9x4.7x
Sat, 23 Dec 2023US$1.7tUS$375.2bUS$33.9b26.7x49.3x4.4x
Mon, 20 Nov 2023US$1.6tUS$375.1bUS$34.0b25.8x48.1x4.4x
Wed, 18 Oct 2023US$1.7tUS$381.8bUS$43.8b18.3x39.2x4.5x
Fri, 15 Sep 2023US$1.8tUS$381.8bUS$43.9b18x39.9x4.6x
Sun, 13 Aug 2023US$1.8tUS$381.5bUS$43.9b18.7x40.2x4.6x
Tue, 11 Jul 2023US$1.7tUS$392.8bUS$60.2b19.1x27.8x4.3x
Thu, 08 Jun 2023US$1.7tUS$393.0bUS$60.5b18.7x28.3x4.4x
Sat, 06 May 2023US$1.7tUS$393.0bUS$59.5b19.4x28.8x4.4x
Mon, 03 Apr 2023US$1.6tUS$401.2bUS$69.4b16.1x22.8x3.9x
Wed, 01 Mar 2023US$1.5tUS$401.4bUS$69.6b17.6x22.2x3.9x
Fri, 27 Jan 2023US$1.7tUS$402.6bUS$69.4b17.6x24.2x4.2x
Sun, 25 Dec 2022US$1.8tUS$403.7bUS$70.7b16.8x24.8x4.4x
Tue, 22 Nov 2022US$1.7tUS$403.7bUS$71.1b13x24.3x4.3x
Thu, 20 Oct 2022US$1.6tUS$403.4bUS$72.1b12.8x22x3.9x
Sat, 17 Sep 2022US$1.6tUS$403.0bUS$71.3b13.8x22.3x3.9x
Price to Earnings Ratio

22.3x


Total Market Cap: US$1.6tTotal Earnings: US$71.3bTotal Revenue: US$403.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.3x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 29.4x which is lower than its 3-year average PE of 52.3x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 5.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.39%
Healthcare1.15%
Pharma0.49%
Pharma0.49%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$750.612.1%
+US$13.8b		-16.7%PE48.8x
TEVA Teva Pharmaceutical IndustriesUS$19.685.0%
+US$1.1b		12.3%PS1.4x
ELAN Elanco Animal HealthUS$18.765.1%
+US$452.1m		29.2%PE21.5x
RAPP Rapport TherapeuticsUS$28.0371.2%
+US$425.6m		42.0%PB3.9x
NKTR Nektar TherapeuticsUS$48.5767.0%
+US$370.6m		161.1%PS12.3x

Latest News

JNJ
US$176.96
Johnson & Johnson
7D
-0.6%
1Y
5.7%
RAPP
US$28.03
Rapport Therapeutics
7D
71.2%
1Y
42.0%
LLY
US$750.61
Eli Lilly
7D
2.1%
1Y
-16.7%
NKTR
US$48.57
Nektar Therapeutics
7D
67.0%
1Y
161.1%
PFE
US$24.71
Pfizer
7D
-1.1%
1Y
-16.9%
ELAN
US$18.76
Elanco Animal Health
7D
5.1%
1Y
29.2%
MRK
US$84.61
Merck
7D
-1.0%
1Y
-26.6%
WVE
US$7.48
Wave Life Sciences
7D
-22.2%
1Y
25.5%
BMY
US$47.23
Bristol-Myers Squibb
7D
-0.4%
1Y
-4.2%

Aging Demographics And Genomics Will Drive Healthcare Demand

Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.
OGN
US$10.37
Organon
7D
10.1%
1Y
-48.4%
TEVA
US$19.68
Teva Pharmaceutical Industries
7D
5.0%
1Y
12.3%
CRNX
US$36.50
Crinetics Pharmaceuticals
7D
9.6%
1Y
-27.6%
ALTS
US$4.01
ALT5 Sigma
7D
-28.1%
1Y
97.5%

Take Care Before Jumping Onto ALT5 Sigma Corporation (NASDAQ:ALTS) Even Though It's 25% Cheaper

Aug 20
Take Care Before Jumping Onto ALT5 Sigma Corporation (NASDAQ:ALTS) Even Though It's 25% Cheaper
HRMY
US$34.00
Harmony Biosciences Holdings
7D
-8.4%
1Y
-9.5%
ZTS
US$149.79
Zoetis
7D
-2.0%
1Y
-21.7%
RGC
US$13.57
Regencell Bioscience Holdings
7D
5.6%
1Y
8,072.1%